This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (44)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Ophthalmology, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Chang-Sue Yang, MD; Joseph A. Khawly, MD; Dean P. Hainsworth, MD; San-Ni Chen, MD; Paul Ashton, PhD; Hong Guo, MD; Glenn J. Jaffe, MD

Arch Ophthalmol. 1998;116:69-77.

Objective  To determine the efficacy and pharmacokinetics of an intravitreal sustained-release triamcinolone acetonide and 5-fluorouracil (TA/5-FU) codrug in the treatment of experimental proliferative vitreoretinopathy (PVR).

Methods  The therapeutic efficacy of the TA/5-FU codrug was determined in a rabbit model that simulates human PVR. Intravitreal levels of triamcinolone and 5-fluorouracil were measured at different time points and drug release in vitro was tested. Toxic effects were evaluated by electroretinograpy, clinical examination, and light microscopy.

Results  Both the severity of PVR grade and the percentage of eyes with moderate or worse tractional detachment were significantly less in eyes treated with the codrug. The therapeutic effect of the intravitreal codrug was paralleled by sustained intravitreal levels of triamcinolone and 5-fluorouracil. There were no drug-related toxic effects evident on clinical or histopathologic examination of eyes containing the TA/5-FU codrug.

Conclusions  The intravitreal sustained-release TA/5-FU codrug effectively inhibits the progression of PVR in a rabbit model that closely resembles PVR in humans. The TA/5-FU codrug may simultaneously target different components of the wound-healing response.

From the Departments of Ophthalmology, Duke University, Durham, NC (Drs Yang, Khawly, Hainsworth, Chen, and Jaffe); and Tufts New England Medical Center, Boston, Mass (Drs Ashton and Guo).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Effect of Alkylphosphocholines on Intraretinal Proliferation Initiated by Experimental Retinal Detachment
Eibl et al.
IOVS 2007;48:1305-1311.
ABSTRACT | FULL TEXT  

Inhibition of Human Retinal Pigment Epithelial Cell Attachment, Spreading, and Migration by Alkylphosphocholines
Eibl et al.
IOVS 2006;47:364-370.
ABSTRACT | FULL TEXT  

An intravitreal biodegradable sustained release naproxen and 5-fluorouracil system for the treatment of experimental post-traumatic proliferative vitreoretinopathy
Cardillo et al.
Br J Ophthalmol 2004;88:1201-1205.
ABSTRACT | FULL TEXT  

Safety of an Intravitreal Injection of Triamcinolone: Results From a Randomized Clinical Trial
Gillies et al.
Arch Ophthalmol 2004;122:336-340.
ABSTRACT | FULL TEXT  

Alkylphosphocholines Inhibit Proliferation of Human Retinal Pigment Epithelial Cells
Eibl et al.
IOVS 2003;44:3556-3561.
ABSTRACT | FULL TEXT  

Intravitreal triamcinolone acetonide for exudative age related macular degeneration
Jonas et al.
Br J Ophthalmol 2003;87:462-468.
ABSTRACT | FULL TEXT  

Intraocular pressure after intravitreal injection of triamcinolone acetonide
Jonas et al.
Br J Ophthalmol 2003;87:24-27.
ABSTRACT | FULL TEXT  

Matrix metalloproteinase biology applied to vitreoretinal disorders
SETHI et al.
Br J Ophthalmol 2000;84:654-666.
FULL TEXT  

New developments in sustained release drug delivery for the treatment of intraocular disease
VELEZ and WHITCUP
Br J Ophthalmol 1999;83:1225-1229.
FULL TEXT